Clinical Study
Aggressive versus Low Dose Inhibition of the Renin-Angiotensin System for the Treatment of Microalbuminuria in Type 2 Diabetic Patients: A Pilot Study
Table 1
Characteristics (mean ± SD where applicable) at randomization.
| | Low dose | Aggressive | P value |
| | Number of subjects | 12 | 11 | | | Age (years) | 54.4 ± 6.7 | 51.6 ± 5.9 | NSa | | Males/females | 5/7 | 7/4 | | | Duration of diabetes (years) | 12.8 ± 5.4 | 7.1±3.1 | <0.01 | | Race/ethnicity | | | | | Latino | 10 | 10 | | | African American | 2 | 0 | | | Caucasian | 0 | 1 | | | Alb/creat (mg/g) | 162.7 ± 94.0 | 142.2 ± 72.4 | NS | | Visit systolic BP (mm Hg) | 126.2 ± 7.1 | 119.7 ± 10.6 | NS | | Visit diastolic BP (mm Hg) | 74.3 ± 10.8 | 73.4 ± 5.5 | NS | | 24-Hour systolic BP (mm Hg) | 125.9 ± 6.8 | 120.9 ± 10.3 | NS | | 24-Hour diastolic BP (mm Hg) | 73.7 ± 8.7 | 70.7 ± 4.3 | NS | | 12-Hour AM systolic BP (mm Hg) | 129.0 ± 6.5 | 122.0 ± 10.2 | NS | | 12-Hour AM diastolic BP (mm Hg) | 75.9 ± 8.7 | 72.2 ± 5.0 | NS | | 12-Hour PM systolic BP (mm Hg) | 123.1 ± 9.1 | 119.4 ± 10.6 | NS | | 12-Hour PM diastolic BP (mm Hg) | 71.7 ± 10.0 | 69.2 ± 4.8 | NS | | Body mass index | 32.2 ± 5.9 | 33.7 ± 3.9 | NS | | HbA1c (%) | 7.1 ± 0.6 | 6.7 ± 0.6 | NS | | eGFR (mL/min/1.73 m2)b | 108.7 ± 21.6 | 100.5 ± 33.7 | NS | | Right CIMT (mm)b | 0.74 ± 0.09 | 0.72 ± 0.17 | NS | | Left CIMT (mm)b | 0.78 ± 0.16 | 0.74 ± 0.16 | NS | | () | () | | | PAT-Hyperemia-induced (fold increase)b | 2.2 ± 0.5 | 2.0 ± 0.7 | NS | | PAT-NTG-induced (fold increase)b | 1.9 ± 0.8 | 1.4 ± 0.6 | NS | | hs-C-reactive proteinb (mg/L)b | 4.3 ± 3.6 | 4.1 ± 3.1 | NS |
|
|
a; blog transformed; BP: blood pressure; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; CIMT: carotid intima medial thickness; PAT: peripheral arterial tonometry; hs-CRP: highly sensitive C-reactive protein.
|
